header”></head>

<body data-rsssl=1 class=

Risk of False Results with the Curative SARS-Cov-2 Test for COVID-19

The U.S. Food and Drug Administration (FDA) is alerting patients and healthcare providers of the risk of false results, particularly false negative results, with the Curative SARS-Cov-2 test. Risks to a patient of a false negative result include: delayed or lack of supportive treatment; lack of monitoring of infected individuals and their household or other

By |2021-01-07T17:16:46+00:00January 7th, 2021|alerts|Comments Off on Risk of False Results with the Curative SARS-Cov-2 Test for COVID-19

Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg

Nostrum Laboratories, Inc. is voluntarily recalling one lot of Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) at the consumer level. The Metformin HCl Extended Release Tablets, USP 750 mg have been found to contain levels of nitrosamine impurities above the ADI limit of 96 ng/day as published in the

By |2021-01-07T17:14:14+00:00January 7th, 2021|alerts|Comments Off on Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg

FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines

Two different mRNA vaccines have now shown remarkable effectiveness of about 95 percent in preventing COVID-19 disease in adults. As the first round of vaccine recipients become eligible to receive their second dose, we want to remind the public about the importance of receiving COVID-19 vaccines according to how they’ve been authorized by the FDA

By |2021-01-07T17:11:56+00:00January 7th, 2021|alerts|Comments Off on FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines